**CLAIMS:**

1. A stent comprising

    a. a stent framework;

    b. a plurality of layers deposited on said stent framework to form said stent; wherein at least one of said layers comprises a 50:50 PLGA bioabsorbable polymer and at least one of said layers comprises rapamycin, and each respective layer when initially deposited is done so in an alternating manner;

    wherein at least 10% of the rapamycin is in crystalline form,

    wherein the stent elutes at most 50% of the rapamycin in vitro at day 10 after the stent is contacted with an elution media comprising ethanol (5%) wherein a pH of the media is about 7.4 and wherein the elution media is at a temperature of about 37°C.

2. The stent of Claim 1, wherein the stent elutes at least 30% of the rapamycin in vitro at day 10.

3. The stent of Claim 1, wherein the elution media is static during elution or is agitated during elution.

4. The stent of Claim 1, wherein the stent elutes at most 40% of the rapamycin in vitro at day 10 when the elution media is static during elution.

5. The stent of Claim 1, wherein the stent elutes at least 10% of the rapamycin in vitro at day 10.

6. The stent of Claim 1, wherein the stent elutes at least 50 micrograms of the rapamycin in vitro at day 10.

7. The stent of Claim 1, wherein the stent elutes at most 60 micrograms of the rapamycin in vitro at day 10 when the elution media is static during elution.

8. The stent of Claim 1, wherein the stent elutes at least 25 micrograms of the rapamycin in vitro at day 10.

9. A method of preparing a stent comprising:

a. providing a stent framework;

b. depositing a coating on said stent framework to form said stent; wherein said coating comprises rapamycin and a polymer wherein at least 10% of the rapamycin is in crystalline form and the polymer comprises a 50:50 PLGA bioabsorbable polymer, wherein depositing said coating comprises alternating deposits of polymer particles on said framework in dry powder form and deposits of rapamycin particles on said framework in dry powder form; and

c. sintering said coating under conditions that do not substantially modify the morphology of the rapamycin,

wherein the stent elutes at most 50% of the rapamycin in vitro at day 10 after the stent is contacted with an elution media comprising ethanol (5%) wherein a pH of the media is about 7.4 and wherein the elution media is at a temperature of about 37°C.

10. The method of Claim 9, wherein the stent elutes at least 30% of the rapamycin in vitro at day 10.

11. The method of Claim 9, wherein the elution media is static during elution or is agitated during elution.

12. The method of Claim 9, wherein the stent elutes at most 40% of the rapamycin in vitro at day 10 when the elution media is static during elution.

13. The method of Claim 9, wherein the stent elutes at least 10% of the rapamycin in vitro at day 10.

14. The method of Claim 9, wherein the stent elutes 75 micrograms or less of the rapamycin in vitro at day 10 after the stent is contacted with an elution media comprising ethanol (5%).